DApagliflozin 10 mg and VildagliptiN 100 mg SR use in Cardiology Practice A real world Clinical Insight (DAa-ViNCI Study)
Main Article Content
Abstract
Background: Diabetes mellitus is a global epidemic characterized by persistently high blood sugar levels. The combination of dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) is potentially effective in managing type 2 diabetes mellitus (T2DM). The present study analyzed the efficacy, safety, and practice patterns of the fixed-dose (FDC) of vildagliptin 100 mg and dapagliflozin 10 mg in cardiology practice.
Methods: This retrospective, non-randomized, non-comparative, multi-center study was conducted at 200 sites across India from June 2023 to March 2024. Patients of either sex, >18 years of age, diagnosed with T2DM, and who received the FDC of vildagliptin 100 mg SR and dapagliflozin 10 mg for the treatment of their condition were included. Comprehensive patient information collected from the medical records were analyzed.
Results: A total of 2,199 patients were included, with a mean age of 55.04 years. Approximately 63% of the patients were male. Hypertension (74.81%) was the most common comorbidity, followed by dyslipidemia (38.52%). The FDC of vildagliptin 100 mg SR and dapagliflozin 10 mg reduced the mean glycated hemoglobin (7.7% vs 5.8%), fasting plasma glucose (142.4 mg/dL vs 90.2 mg/dL), postprandial glucose (205.64 mg/dL vs 123.38 mg/dL) levels from baseline to 3 months. The mean systolic blood pressure decreased from 141.35 mmHg to 131.59 mmHg, and the mean diastolic blood pressure decreased from 89.65 mmHg to 84.42 mmHg following FDC therapy. Glycemic goals were achieved in 78.08% of patients. Adverse events were reported in 0.36% of patients.
Conclusion: The FDC of vildagliptin and dapagliflozin demonstrated substantial efficacy in managing T2DM and was well-tolerated, with a low incidence of adverse events.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [published correction appears in Diabetes Res Clin Pract. 2023;204:110945.
3. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
4. Hinnen D, Kruger D, Magwire M. Type 2 diabetes and cardiovascular disease: risk reduction and early intervention. Postgraduate medicine. 2023; 135(1):2-12.
5. Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther. 2022;13(5):1097-1114.
6. Alam MS, Aqil M, Qadry AK, Kapu P, Pillai KK. Utilization pattern of oral hypoglycaemic agents for type 2 diabetes mellitus patients attending out-patient department at a University Hospital in New Delhi. Pharmacol Pharm. 2014;5:636–45.
7. Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12(12):1407-17.
8. Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep. 2018;8(1):4466.
9. Mathieu C, Kozlovski P, Paldánius PM, Foley JE, Modgill V, Evans M, et al. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13(2):68-72.
10. Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019;79(10):1135-46.
11. Phrommintikul A, Wongcharoen W, Kumfu S, Jaiwongkam T, Gunaparn S, Chattipakorn S, et al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019;85(6):1337-47.
12. Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(7):616-21.
13. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38(3):373-5.
14. Akshay Bafna, Mehta A, Garg R, Jayagopal Pathiyil Balagopalan, Rajput R, Nitin Zalte, et al. Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice. Journal of Diabetology. 2024;15(2):183–92.
15. Xie J, Wang M, Long Z, Ning H, Li J, Cao Y, et al. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: Systematic analysis of the Global Burden of Disease Study 2019. BMJ. 2022;379:e072385.
16. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 2021; 69:2932–8.
17. Rajbhandari SM, Kumar KV, Selvarajan R, Murali T. High prevalence of diabetes in young people in Bangalore, India. Br J Diabetes. 2020;20:104–6.
18. India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: The global burden of disease study 1990-2016. Lancet Glob Health 2018;6:e1352–62.
19. Nagarathna R, Bali P, Anand A, Srivastava V, Patil S, Sharma G, et al. Prevalence of diabetes and its determinants in the young adults indian population-call for yoga intervention. Front Endocrinol (Lausanne) 2020;11:507064.
20. Manjula S, and Krishna Kumar M. Expert Opinion on the Use of Vildagliptin in Indian Patients with Diabetes Mellitus. Asian Journal of Research and Reports in Endocrinology. 2024;7(1):11-19.
21. Agrawala RK, Akbar SS, Kaushik Biswas DN, Garg UK, Warrier S, Prasad A, et al. The Use of Vildagliptin-Dapagliflozin Fixed Dose Combination in Different Patient Profiles in Indian Settings: An Opinion-Based Consensus. International Journal of Clinical and Surgical Research & Reviews. 2023;6 (03):2010-17.
22. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376-83.
23. Dharmalingam M, Kumar Sharma S, Prakash V, Maiti A, Kumar R, Murthy LSS, et al. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin. Cureus. 2024;16(4):e58115.
24. Petchiappan V, Mathew E, Jose J, Fardan M, Chidambaram Y, Thangavelu S. Use of Fixed-dose Combination Therapy with Remogliflozin and Vildagliptin as an Add-on Drug in Improving the Glycemic Control of Type 2 Diabetes Mellitus: An Observational Study. Journal of Pharmacology and Pharmacotherapeutics. 2023;14(1):72-78.
25. Real-world effectiveness of dapagliflozin and sitagliptin fixed-dose combination in Indian patients with type 2 diabetes: a retrospective analysis of electronic medical records stratified by BMI. Available from:
https://www.endocrine-abstracts.org/ea/0099/ea0099ep639
26. Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2017;40(2): 201-09.